MDMA

Latest Headlines

Following the release of the federal government's fiscal year 2014 omnibus appropriations legislation on Monday, medical device industry professionals lauded the government's decision to restore user fees that were lost in 2013 due to the sequester.

As an 11th-hour budget deal shapes up for votes in the House and Senate this week, AdvaMed president and CEO Stephen J. Ubl lauded parts of the agreement that call for relief of the FDA user fee sequestration.

AdvaMed has steadily ramped up its lobbying spending as part of the push to repeal the 2.3% medical device tax. But spending on lobbying by the Medical Device Manufacturers Association, which represents a lot of smaller device companies, has remained small and constant since early 2009, Roll Call reported.

Now that the IRS has unveiled its final rule on the medical device tax, some in the industry say there's not enough time for devicemakers to get their compliance ducks in a row before the 2.3% charge takes effect Jan. 1.

THE LIBRARY: WHITEPAPER

So-called "orphan diseases" are rare conditions that affect fewer than 200,000 people per year in the U.S. In this Executive Insights, L.E.K. Consulting looks at the changing dynamics of the orphan market and identifies winning strategies designed to capture value within this sector. Download today!